Form 4/A for MNKD MANNKIND CORP
Accepted 2022-08-24 00:00:00 ET · period of report 2022-01-31 · accession 0001209191-22-047421 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2022-08-24 | 2022-01-31 | MNKD | Galindo Alejandro | EVP Endocrine Business Unit | A - Grant | $3.17 | +1,804 | 539.8K | +0.3% | +$5,719 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock, $0.01 Par Value | 2022-01-31 | A | A | 1,804 | $3.17 | 539,790 | D | — | — |